Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385509 | 0.88 | HTR1A (0.39) | KMT2AHTR1AL3MBTL1LMNAKDM4E | |
| SCHEMBL5389361 | 0.87 | CYP1B1 (0.41) | KMT2ACYP1B1MAPTMAOAMAOB | |
| SCHEMBL5393470 | 0.82 | KMT2A (0.41) | KMT2AHTR1AL3MBTL1LMNAKDM4E | |
| SCHEMBL5381978 | 0.80 | ALOX15 (0.36) | KMT2AKDM4EESR1MAPTMAOA | |
| SCHEMBL5385273 | 0.79 | THRB (0.54) | KMT2AHTR1AL3MBTL1LMNAKDM4E | |
| SCHEMBL5385626 | 0.79 | THRB (0.49) | KMT2AHTR1AL3MBTL1LMNAKDM4E | |
| SCHEMBL5089442 | 0.73 | KMT2A (0.71) | KMT2AHTR1ALMNAKDM4EESR1 | |
| SCHEMBL14543843 | 0.72 | CYP3A4 (0.48) | L3MBTL1LMNAESR1MAPTMAOA | |
| SCHEMBL14519768 | 0.72 | CYP3A4 (0.48) | L3MBTL1LMNAESR1MAPTMAOA | |
| SCHEMBL5391906 | 0.71 | LMNA (0.42) | KMT2AHTR1AL3MBTL1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2004-05-20 | — | — | US | disclosed |
| EP-1296936-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098256-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | TSHR, THRA, THRB | KMT2A 4239/4885HTR1A 397/4885L3MBTL1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.